ADXS, AZN start phase-2 trial of ADXS-HPV + Durvalumab (AZN’s checkpoint inhibitor) in HPV-associated (cervical, H&N) cancers: http://finance.yahoo.com/news/advaxis-medimmune-commence-enrollment-phase-130500622.html